Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone

Journal of Endocrinological Investigation

Volumn 35, Issue 9, 2012, Pages 866-868

  Piemonte, S ^a   Romagnoli, E ^a   Bratengeier, C ^b   Woloszczuk, W ^c   Tancredi, A ^a   Pepe, J ^a   Cipriani, C ^a   Minisola, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Biomarker Design Forschungs GmbH   (Austria)

^c Biomedica   (Austria)

Author keywords

Osteoporosis treatment; Parathyroid hormone; Sclerostin

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; SCLEROSTIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; POSTMENOPAUSE; PROGNOSIS;

EID: 84869013738     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8522     Document Type: Article

References (18)

1. van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005, 16: 319-27.
2. Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 2007, 38: 261-9.
3. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280: 19883-7.
4. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011, 26: 229-38.
5. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10: 537-43.
6. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39: 91-7.
7. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010, 25: 178-89.
8. Leupin O, Kramer I, Collette NM, et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 2007, 22: 1957-67.
9. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146: 4577-83.
10. Drake MT, Srinivasan B, Mödder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010, 10: 5056-62.
11. Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 2011, 96: 1555-9.
12. Piemonte S, Romagnoli E, Cipriani C, et al. The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1,25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study. Calcif Tissue Int 2009, 85: 287-92.
13. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 2012, 50: 739-42.
14. Chung YE, Lee SH, Lee SY, et al. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int 2011, 23: 1235-43.
15. Mazzuoli G, Marinucci D, D'Erasmo E, et al. Cyclical behavior of bone remodeling and bone loss in healthy women after menopause: results of a prospective study. Bone 2002, 31: 718-24.
16. Sutherland MK, Geoghegan JC, Yu C, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004, 35: 828-35.
17. Baron R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148: 2635-43.
18. Canalis E, Giustina A, Bilezikian JP. Mechanism of anabolic therapies for osteoporosis N Engl J Med 2007, 357: 905-16.